ArticleAvicenna journal of phytomedicine
Effect of a Persian medicine formula, Glasthma, on lung function and intestinal permeability in Asthma: A triple-blind randomized controlled trial.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate Glasthma, a Persian medicine herbal formulation for its efficacy and safety in managing asthma symptoms and modulating intestinal permeability. Materials and Methods: Forty randomly assigned asthma patients received Glasthma syrup (n=20) or a placebo (n=20) twice daily for 4 weeks. Respiratory symptoms, pulmonary function tests, and 5-hour urine lactulose to mannitol ratio were assessed at baseline and after 4 weeks. Results: Glasthma group exhibited significant improvements in clinical and paraclinical scores, including asthma control test (p<0.001), asthma control questionnaire 7 (p<0.007), Forced Expiratory Volume in the First Second (p<0.001), and Maximal Mid-Expiratory Flow 25-75 (p<0.002) compared to the placebo group. Lactulose and mannitol levels significantly decreased in the Glasthma group (p<0.028 and p<0.0000, respectively), with no significant changes in the ratio. No serious adverse effects were observed. Conclusion: These findings suggest that Glasthma formulation may effectively improve asthma symptoms and regulate the gut-lung axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.